Communicating about medicine means making claims that are checked by clinicians, journalists and regulators, often in that order. A programme built like consumer publicity, aiming for volume and momentum, tends to produce a correction or a complaint. The discipline here is evidence first, and the communication is the last step rather than the first.
The claim is the deliverable
What may be said about a treatment, a device or an outcome is decided by the evidence and the regulatory category, not by the communications plan. Promotional claims about regulated products carry specific requirements, and a service can still mislead by implying outcomes it cannot support. The claim set and its evidence should exist before a single pitch is written.
Health journalists check
Specialist reporters read the study, ask about sample size and design, and will contact independent experts. That is a feature rather than an obstacle: a programme built on genuine evidence performs well under that scrutiny, and one built on a press release drafted from a marketing summary does not survive it.
Patient stories need paperwork
Any identifiable patient material used for marketing needs a valid authorisation, and consent to treatment is not consent to publication. Record what may be used, where and for how long, and that it can be withdrawn. This is the most common compliance failure in medical communications.
Crisis and adverse events
Product problems, adverse events and clinical incidents carry reporting obligations that run in parallel with public communication and take precedence. The plan worth having is written in advance: who speaks, what is said before the cause is known, and how the regulatory and public tracks are kept consistent.
Questions people ask about medical pr agency
Can a practice or company promote an off-label use?
Promotion of unapproved uses is restricted and is an enforcement area. What may be discussed, and in what setting, is a regulatory question for counsel rather than a communications decision.
Are patient testimonials allowed?
With valid authorisation, and results shown should be typical or the variation disclosed. Any incentive given must be disclosed as a material connection.
How is medical PR measured?
By coverage in the publications clinicians and patients actually read, by accuracy of the resulting reporting, and by referral or enquiry effect. Volume alone rewards pitching rather than credibility.